Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
2009 3
2010 3
2011 1
2012 1
2013 1
2014 3
2015 5
2016 8
2017 5
2018 5
2019 3
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Results by year
Filters applied: . Clear all
Page 1
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, Xi C, Su GH, Xu L, Posey J 3rd, Jiang W, Yeo CJ, Golan T, Pishvaian MJ, Brody JR. Dhir T, et al. Mol Cancer Res. 2019 Oct;17(10):2029-2041. doi: 10.1158/1541-7786.MCR-19-0589. Epub 2019 Aug 5. Mol Cancer Res. 2019. PMID: 31383722 Free PMC article.
We determined that inhibitors of HuR (ELAVL1), a prosurvival mRNA stability factor that regulates cyclin D1, and an inhibitor of Yes-Associated Protein 1 (YAP1), a pro-oncogenic, transcriptional coactivator important for CDK6 and cyclin D1, were both synergistic wit …
We determined that inhibitors of HuR (ELAVL1), a prosurvival mRNA stability factor that regulates cyclin D1, and an inhibitor …
Complex HuR function in pancreatic cancer cells.
Brody JR, Dixon DA. Brody JR, et al. Wiley Interdiscip Rev RNA. 2018 May;9(3):e1469. doi: 10.1002/wrna.1469. Epub 2018 Feb 16. Wiley Interdiscip Rev RNA. 2018. PMID: 29452455 Free PMC article. Review.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with dismal patient outcomes. The underlying core genetic drivers of disease have been identified in human tumor specimens and described in genetically engineered mouse models. ...Speci
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with dismal patient outcomes. The underlying core ge
Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.
Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR. Jain A, et al. Cancer Res. 2019 Sep 1;79(17):4491-4502. doi: 10.1158/0008-5472.CAN-18-3645. Epub 2019 Jul 4. Cancer Res. 2019. PMID: 31273064 Free PMC article.
We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (ELAVL1). ...SIGNIFICANCE: PARG is a potential target in pancreatic cancer as a single-agent …
We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic …
Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy.
Li L, Chen H, Gao Y, Wang YW, Zhang GQ, Pan SH, Ji L, Kong R, Wang G, Jia YH, Bai XW, Sun B. Li L, et al. Mol Cancer Ther. 2016 Sep;15(9):2232-43. doi: 10.1158/1535-7163.MCT-16-0008. Epub 2016 Jul 1. Mol Cancer Ther. 2016. PMID: 27371730 Free article.
Recently, pancreatic ductal adenocarcinoma (PDAC) has emerged as one of the most aggressive malignant tumors with the worst prognosis. ...MALAT1 was speculated to regulate tumorigenesis via HuR-TIA-1-mediated autophagic activation. Hence, we investigated the biologi …
Recently, pancreatic ductal adenocarcinoma (PDAC) has emerged as one of the most aggressive malignant tumors with the worst prognosis …
CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
Lal S, Cheung EC, Zarei M, Preet R, Chand SN, Mambelli-Lisboa NC, Romeo C, Stout MC, Londin E, Goetz A, Lowder CY, Nevler A, Yeo CJ, Campbell PM, Winter JM, Dixon DA, Brody JR. Lal S, et al. Mol Cancer Res. 2017 Jun;15(6):696-707. doi: 10.1158/1541-7786.MCR-16-0361. Epub 2017 Feb 27. Mol Cancer Res. 2017. PMID: 28242812 Free PMC article.
The RNA-binding protein HuR (ELAVL1) supports a pro-oncogenic network in gastrointestinal (GI) cancer cells through enhanced HuR expression. ...Importantly, HuR-deficient MIA PaCa-2 and Hs 766T cells were unable to engraft tumors in vivo compared with …
The RNA-binding protein HuR (ELAVL1) supports a pro-oncogenic network in gastrointestinal (GI) cancer cells through enhanced …
Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A, Jasukaitiene A, Silkuniene G, Barauskas V, Gulbinas A, Dambrauskas Z. Lukosiute-Urboniene A, et al. World J Gastroenterol. 2019 Jan 14;25(2):205-219. doi: 10.3748/wjg.v25.i2.205. World J Gastroenterol. 2019. PMID: 30670910 Free PMC article.
AIM: To determine the association of human antigen R (HuR) and inhibitors of apoptosis proteins (IAP1, IAP2) and prognosis in pancreatic cancer. METHODS: Protein and mRNA expression levels of IAP1, IAP2 and HuR in pancreatic ductal …
AIM: To determine the association of human antigen R (HuR) and inhibitors of apoptosis proteins (IAP1, IAP2) and …
Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.
Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA. Peng W, et al. Mol Cell Biol. 2018 Jan 16;38(3):e00427-17. doi: 10.1128/MCB.00427-17. Print 2018 Feb 1. Mol Cell Biol. 2018. PMID: 29133460 Free PMC article.
Human antigen R (ELAVL1; HuR) is perhaps the best-characterized RNA-binding protein. Through its overexpression in various tumor types, HuR promotes posttranscriptional regulation of target genes in multiple core signaling pathways associ
Human antigen R (ELAVL1; HuR) is perhaps the best-characterized RNA-binding protein. Through its overexpr
Reduced expression of the RNA-binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27(Kip1) levels and poor prognosis.
Kim C, Jeong DE, Heo S, Ji E, Rho JG, Jung M, Ahn S, Kim YJ, Kim YS, Nam SW, Kulkarni RN, Lee KB, Lee EK, Kim W. Kim C, et al. J Pathol. 2018 Oct;246(2):231-243. doi: 10.1002/path.5135. Epub 2018 Aug 28. J Pathol. 2018. PMID: 30014466 Free PMC article.
HuD expression was frequently lost in many human pancreatic NETs, and these pancreatic NETs showed aggressive clinicopathological phenotypes with low p27 levels, increased tumor size, higher World Health Organization grade and pT stage of the tumor, and the p …
HuD expression was frequently lost in many human pancreatic NETs, and these pancreatic NETs showed aggressive clinicopa …
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J. Elebro J, et al. Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11. Acta Oncol. 2016. PMID: 26362587 Free PMC article.
BACKGROUND: Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other types of periampullary adenocarcinoma. ...The RNA-binding protein human antigen R (HuR) has been demonstrated to con …
BACKGROUND: Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other type …
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR. Tatarian T, et al. Ann Surg. 2018 Feb;267(2):364-369. doi: 10.1097/SLA.0000000000002088. Ann Surg. 2018. PMID: 27893535 Free PMC article. Clinical Trial.
BACKGROUND: Previous studies have implicated the mRNA-binding protein, HuR (ELAVL1), as a predictive marker for PDA treatment response in the adjuvant setting. ...METHODS: Tissue samples from 379 patients with PDA enrolled in the European Study Group of Pancreati
BACKGROUND: Previous studies have implicated the mRNA-binding protein, HuR (ELAVL1), as a predictive marker for PDA treatment …
37 results
Jump to page
Feedback